Registry update — unassessed
Metformin in Longevity Study (MILES).
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: May 21, 2021 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- Whether metformin actually changed gene expression profiles or had any biological effect, as no results are presented.
- Whether any observed changes would be clinically meaningful or affect lifespan or age-related disease risk.
- Whether effects, if present, would extend to individuals without impaired glucose tolerance or diabetes.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Older adults with impaired glucose tolerance (IGT), compared to young healthy subjects
- Primary outcome
- Restoration of gene expression profile to that of young healthy subjects
- Effect size
- —
- Significance
- Not reported
- Journal
- Albert Einstein College of Medicine
- Published
- May 21, 2021
Sources
Primary source
- Albert Einstein College of Medicine ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The investigators therefore propose a pilot study to examine the effect of metformin treatment on the biology of aging in humans.
whether treatment with metformin will restore the gene expression profile of older adults with impaired glucose tolerance (IGT) to that of young healthy subjects.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.